Carnitine Deficiency Induced During Hæmodialysis

Battistella, P. A.; Angelini, C.; Vergani, L; Bertoli, M; Lorenzi, Sandra

doi:10.1016/s0140-6736(78)90714-6

Cited by 39 publications

(15 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The weekly loss of carnitine in the dialysate in RDT was 1.518 ± 273. in IPD 1.175 ± 238. and in CAPD patients 1.078 ± 14pmol [17], Similar results have been reported by Leschkeet al [13]. According to Battistella et al [22], HD patients can be subdivided into 2 groups, one in which there is a return to normal or higher plasma carnitine and another in which a chronic plasma carnitine deficiency is established by dial ysis. Addition of L-carnitine to the dialysate (final con centration of 65 pmol/l) completely prevented the fall of plasma carnitine during HD [23].…”

Section: Discussionsupporting

confidence: 76%

Serum Free Carnitine, Carnitine Esters and Lipids in Patients on Peritoneal Dialysis and Hemodialysis

et al. 1986

View full text Add to dashboard Cite

Serum free and esterified carnitine levels as well as lipids were investigated in patients undergoing regular hemodialysis (HD) treatment before and during 12 weeks of treatment with L-carnitine (1 g i.v.) at the end of each HD. The results were compared with those obtained in patients on continuous ambulatory peritoneal dialysis (CAPD; n = 15) or intermittent peritoneal dialysis (IPD; n = 3) and healthy controls (CO; n = 20). In HD patients (n = 23) total carnitine (TC) was 49.9 ± 3.9 (CO: 46.0 ± 2.5; NS), free carnitine (FC) was 31.6 ± 2.8 (CO: 37.4 ± 1.3; p < 0.05), short-chain acylcarnitine (SCC) was 17.0 ± 1.8 (CO: 7.2 ± 0.9; p < 0.0001) and long-chain acylcarnitine (LCC) was 1.2 ± 0.2 μmol/l (CO: 0.6 ± 0.1; p < 0.05). FC was in the normal range in CAPD (35.6 ± 3.2) and IPD (44.5 ± 8.0 μmol/l) patients, whereas SCC (30.1 ± 3.5) and LCC (2.9 ± 0.2) levels were maximal elevated in IPD patients (11.8 ± 0.8 and 1.5 ± 0.2 on CAPD). Therefore, TC was higher in IPD than in CAPD patients (77.5 ± 5.0 vs. 49.0 ± 3.5 μmol/l). 12 weeks after L-carnitine supplementation in HD patients, TC was 313.9 ± 22.6, FC was 207.7 ± 12.4, SCC was 99.6 ± 12.1 and LCC was 7.1 ± 0.6 μmol/l. TC and FC were significantly lower in females compared with males. Total cholesterol and ketone bodies were normal, HDL cholesterol was significantly decreased before and after L-carnitine supplementation. On the other hand, a paradoxical rise in serum triglycerides was observed. Our data indicate abnormalities of free and esterified carnitine in HD, CAPD and IPD patients. The markedly elevated serum levels for TC, FC, SCC and LCC following L-carnitine therapy suggest limited carnitine utilization in chronic uremic patients.

show abstract

Section: Discussionsupporting

confidence: 76%

Serum Free Carnitine, Carnitine Esters and Lipids in Patients on Peritoneal Dialysis and Hemodialysis

et al. 1986

View full text Add to dashboard Cite

show abstract

“…Several studies have shown that HD patients exhibit a constant loss of plasma carnitine through filtration and that subsequent endogenous biosynthesis does not sufficiently restore plasma carnitine to basal levels [7][8][9]. Recently it was reported that plasma-free carnitine deficiency was correlated with time on dialysis [10].…”

Section: Introductionmentioning

confidence: 99%

Effects of <i>L</i>-Carnitine Supplementation on Cardiac Morbidity in Hemodialyzed Patients

Matsumoto

Sato

Ohashi³

et al. 2000

Am J Nephrol

View full text Add to dashboard Cite

Cardiac diseases are well known among patients on maintenance hemodialysis (HD), and carnitine deficiency may be an important factor in cardiac morbidity. We studied the effects of low-dose L-carnitine treatment (500 mg/day) on chest symptoms (dyspnea on exertion, chest pain, palpitation), cardiac function, and left ventricular (LV) mass in 9 HD patients with reduced ejection fraction (EF). After 6 months of L-carnitine treatment, most patients had at least some improvement in chest symptoms, while LVEF was increased and LV mass was decreased. Carnitine fractions increased and reached plateaus at 2–3 times the baseline levels. These results suggest that prolonged low-dose L-carnitine treatment can improve the cardiac morbidity by restoring decreased carnitine tissue levels and impaired oxidation of FFA.

show abstract

“…Several studies have demonstrated that HD patients exhibit a constant loss of plasma carnitine during dialysis and have relative insufficiency of carnitine [7][8][9]. Against this background, some groups have reported beneficial effects of oral supplementation of high-dose L-carnitine (2 g/day) on dialysis-associated muscle symptoms [10,11].…”

Section: Introductionmentioning

confidence: 99%

Effects of <i>L</i>-Carnitine Supplementation on Renal Anemia in Poor Responders to Erythropoietin

et al. 2000

View full text Add to dashboard Cite

While renal anemia can be successfully treated by use of erythropoietin (EPO) in most hemodialysis (HD) patients, some patients have anemia that is refractory to treatment with a high dose of EPO. We examined whether L-carnitine treatment could raise hematocrit (Hct) levels in such patients. Fourteen HD patients who showed a poor response to EPO and no evident factors which inhibit a response to EPO were selected to receive oral L-carnitine (500 mg/day) in a 3-month trial. During the study, 36% of the patients showed Hct increases of more than 2%. Statistical analysis revealed significant increases of Hct (p = 0.003) and total iron-binding capacity (TIBC) (p = 0.050) and a significant decrease of ferritin (p = 0.005). In addition, we found that red blood cells (RBCs) in HD patients contained a comparable level of carnitine to normal controls, despite the presence of serum carnitine deficiency, and that RBC carnitine was not removed through HD, in contrast to serum carnitine. These results suggest that RBC carnitine may be essential for RBCs to perform their metabolic function in renal anemia and that oral L-carnitine treatment could improve anemia in poor responders to EPO.

show abstract

Carnitine Deficiency Induced During Hæmodialysis

Cited by 39 publications

References 1 publication

Serum Free Carnitine, Carnitine Esters and Lipids in Patients on Peritoneal Dialysis and Hemodialysis

Serum Free Carnitine, Carnitine Esters and Lipids in Patients on Peritoneal Dialysis and Hemodialysis

Effects of <i>L</i>-Carnitine Supplementation on Cardiac Morbidity in Hemodialyzed Patients

Effects of <i>L</i>-Carnitine Supplementation on Renal Anemia in Poor Responders to Erythropoietin

Contact Info

Product

Resources

About